<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Regulatory Impact on FinanClub</title>
    <link>https://finan.club/tags/regulatory-impact/</link>
    <description>Recent content in Regulatory Impact on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 11 Jan 2024 09:04:35 +0000</lastBuildDate><atom:link href="https://finan.club/tags/regulatory-impact/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>GDRX</title>
      <link>https://finan.club/us/gdrx/</link>
      <pubDate>Thu, 11 Jan 2024 09:04:35 +0000</pubDate>
      
      <guid>https://finan.club/us/gdrx/</guid>
      <description>score:82
Chances: Shares of GoodRx (GDRX) popped after reporting upbeat preliminary fourth quarter and full year 2023 results. GoodRx unveiled preliminary fourth-quarter revenue that topped analysts&amp;rsquo; estimates. The company has seen &amp;ldquo;great demand&amp;rdquo; for its products, indicating potential growth opportunities. Risks: The company operates in the highly competitive healthcare industry.</description>
    </item>
    
  </channel>
</rss>
